New Findings from Fudan University in Pancreatic Cancer Provides New Insights (Efficacy of Nab-paclitaxel Vs. Gemcitabine In Combination With S-1 for Advanced Pancreatic Cancer: a Multicenter Phase Ii Randomized Trial).

A recent study conducted by Fudan University in Shanghai, China compared the efficacy and safety of two treatment regimens for patients with advanced pancreatic cancer. The study found that the combination of nab-paclitaxel and S-1 showed slightly improved overall survival and significantly improved overall response rate compared to the gemcitabine plus S-1 regimen. The study also observed benefits in patients with KRAS gene mutations and high C-reactive protein levels. While the study did not meet its primary endpoint, the results suggest meaningful clinical activity and warrant further investigation. [Extracted from the article]